William A. Hall, MD, on Prostate Cancer: Results From a Study of Three Treatment Modalities
2017 ASTRO Annual Meeting
William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, and surgery in men with high-risk, nonmetastatic adenocarcinoma of the prostate (Abstract 15).
Shrinivas Rathod, MD, of the University of Manitoba, discusses phase III study results on optimization of treatment of advanced non–small cell lung cancer using radiation therapy and chemotherapy (Abstract 223).
Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation therapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (Presentation 92).
Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session on NSCLC that included discussion of a quality-of-life trial on optimizing treatment; chemotherapy and radiotherapy in advanced disease; a comparison of standard- vs high-dose conformal chemoradiotherapy; and long-term results on a comparison of two stereotactic body radiation therapy schedules in inoperable stage I disease (Abstracts 223, 224, 227, 33).
Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response assessment (Presentation 298).